Life Science News

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Class Period: May 7, 2021 - February 25, 2022
Lead Plaintiff Deadline: June 14, 2022

The complaint alleges that throughout the class period Aurinia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in AUPH: https://www.kleinstocklaw.com/pslra-1/aurinia-pharmaceuticals-inc-loss-submission-form?id=27524&from=1

Lilium N.V. f/k/a Qell Acquisition Corp. (NASDAQ:LILM)
Class Period: March 30, 2021 - March 14, 2022
Lead Plaintiff Deadline: June 17, 2022

The LILM lawsuit alleges that Lilium N.V. f/k/a Qell Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Lilium materially overstates the design and capabilities of the Lilium Jet, an electric vertical take-off-and-landing aircraft for use in a new type of high-speed air transport system for people and goods; (2) Lilium materially overstates the likelihood for the Lilium Jet's timely certification; (3) Lilium misrepresents its ability to obtain or create the necessary batteries for the Lilium Jet; (4) the special purpose acquisition company merger would not and did not generate enough cash to commercially launch the Lilium Jet; (5) Qell Acquisition Corp. did not engage in proper due diligence regarding its merger with Lilium GmbH; and (6) as a result, Defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in LILM: https://www.kleinstocklaw.com/pslra-1/lilium-n-v-f-k-a-qell-acquisition-corp-loss-submission-form?id=27524&from=1

Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. (NYSE: LICY)
Class Period: February 16, 2021 - March 23, 2022
Lead Plaintiff Deadline: June 20, 2022

The complaint alleges Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Li-Cycle's largest customer, Traxys, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li-Cycle's product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company's mark-to-model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company's reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company's gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in LICY: https://www.kleinstocklaw.com/pslra-1/li-cycle-holdings-corp-loss-submission-form?id=27524&from=1

The Klein Law Firm, Friday, May 20, 2022, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/702140/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-AUPH-LILM-and-LICY

News Provided by ACCESSWIRE IA via QuoteMedia

AUP:CA,AUPH
The Gummy Project Announces Official Launch of E-Commerce Sales Channel

The Gummy Project Announces Official Launch of E-Commerce Sales Channel

  • The Gummy Project'S Watermelon Sharks and Peachy Bees are now available for pre-sale purchase at www.shopgummies.com
  • Shipping and fulfilment of online orders will commence on July 11, 2022

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce the official launch of its new e-commerce site at www.shopgummies.com.

"The launch of our e-commerce site is a major milestone, making our product available across Canada for the first time," said Anthony Gindin, Chief Marketing Officer at GUMY. "This really marks our official launch into the Canadian market with e-commerce being a major component in our overall sales channel strategy. The site provides a vehicle for continued growth as well as a platform to share our story and fulfil our mandate to support endangered keystone species."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2022. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.

Resolutions proposed and approved at the AGM were:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

  • The Gummy Project'S Watermelon Sharks and Peachy Bees to be sold at Vancouver based Stong's Markets
  • Stong's are Vancouver owned full-service grocery stores that have operated in Vancouver since 1931

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce that as of June 29, 2022 it has partnered with Stong's to launch its Watermelon Sharks and Peachy Bees into the Canadian retail market.

"This partnership represents another great step in our ongoing sales strategy and we're extremely proud to partner with Stong's, an iconic grocery store in Vancouver," said Charlie Lamb, President and CEO of GUMY. "Following our recent partnership announcements with Flair Airlines and Bard on the Beach, the upcoming launch of our ecommerce site on June 30 2022, and our distribution partnership with Dean's Dairy and Specialty Foods, consumers will soon be able to purchase our products at locations across Canada."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Health Canada Approves OPDIVO® as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma at High Risk of Recurrence after Undergoing Radical Resection of UC

First adjuvant Immunotherapy for patients at high risk of disease recurrence

Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of Compliance with Conditions (NOCc) for OPDIVO ® , as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. i OPDIVO ® is the first immuno-oncology treatment to bring benefit in the adjuvant setting of UC and represents a potential new standard of care for patients at high risk of disease recurrence. ii Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognize and attack cancer cells. iii

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Pivotal ZUMA-5 Study Demonstrates Overall Response Rate of 91% and a Complete Response rate of 77% in Patients Who Received Yescarta After Three or More Lines of Therapy –

Kite's Third Approved Cell Therapy Indication in Europe

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

NDA Resubmission Addresses Issues Related to Vial Compatibility –

If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×